Granted Patent B2

US 12,329,157 · App. 17/247,554 · Granted Jun 17, 2025

Inventors: Catherine Hanson (Saint Paul, MN); Junzhong Li (Saint Paul, MN); Jonathan Scott Killeen (Baden Württemberg, DE); Lisa A. Hellickson (Saint Paul, MN)

Assignee: ECOLAB USA INC.

A01N37/02A01N25/30A01N41/04

Abstract

Claims (26)

1. A virucidal composition comprising:

from about 30 wt-% to about 50 wt-% of a weak acid comprising lactic acid;

from about 5 wt-% to about 30 wt-% of a strong acid comprising methane sulfonic acid;

a C 8 -C 22 alpha olefin sulfonate anionic surfactant;

wherein the composition is a liquid or a solid;

an alkoxylated nonionic surfactant having an EO/PO block copolymer; and

wherein a use pH of the composition is from about 1.5 to about 4.

2. The composition of claim 1 , wherein the alpha olefin sulfonate anionic surfactant comprises from about 0.1 wt-% to about 50 wt-%.

3. The composition of claim 1 , wherein the alpha olefin sulfonate anionic surfactant comprises from about 0.1 wt-% to about 50 wt-%, and the composition further comprises from about 1 wt-% to about 20 wt-% of at least one additional functional ingredient and/or from about 1 wt-% to about 20 wt-% of an additional nonionic surfactant.

4. The composition of claim 1 , wherein the alpha olefin sulfonate anionic surfactant comprises from about 0.1 wt-% to about 50 wt-%, and wherein the nonionic surfactant comprises from about 1 wt-% to about 20 wt-%.

5. The composition of claim 1 , wherein the weak acid is present in an amount of from about 30 wt-% to about 45 wt-% and the strong acid is present in an amount of from about 5 wt-% to about 25 wt-%.

6. The composition of claim 1 , wherein the composition is a liquid or a solid concentrate.

7. The composition of claim 1 , further comprising an additional anionic surfactant.

8. The composition of claim 7 , wherein the additional anionic surfactant is a sulfonate.

9. A method of using a virucidal composition, comprising:

contacting the virucidal composition of claim 1 to a surface in need of treatment, and

inactivating a viral population, wherein the antiviral inactivation is at least a 3 log reduction to complete inactivation within less than about 60 minutes, 30 minutes, 10 minutes, 5 minutes, 1 minute, 30 seconds, or 15 seconds.

10. The method of claim 9 , wherein the virucidal composition is diluted to a use solution before the contacting step, and wherein the diluted use solution is made from about a 0.5% to about a 3% by weight dilution.

11. The method of claim 9 , wherein the contacting is by wiping, dipping, immersing, or spraying.

12. The method of claim 9 , wherein the surface is a hard surface that is a precleaned hard surface, a surface contaminated with norovirus and/or other viral populations, and/or a human or mammalian tissue.

13. The method of claim 9 , wherein the contacting provides complete kill of the virus in less than 1 minute, and wherein the contacting step is at an aqueous use temperature from about 40° F.-160° F.

14. The method of claim 9 , wherein the concentrate is diluted at a rate of from about ⅛ oz./gal. to about 12 oz./gal. to form a use solution of the virucidal composition.

15. The method of claim 9 , wherein a sensor and/or indicator is employed to measure and detect at least one of the following: solution pH at which the composition loses biocidal efficacy, concentration of anionic surfactant in the use solution, fluorescence, and/or conductivity.

16. The method of claim 9 , wherein the virus is human norovirus, Adenovirus and/or Poliovirus.

17. The method of claim 9 , wherein the inactivating of the viral population provides the at least a 3 log reduction to complete inactivation within about 10 minutes, 5 minutes, 1 minute, 30 seconds, or 15 seconds, and wherein the virucidal composition meets the requirements of EN1276, EN13697, EN16615, and/or EN14476 at 18° C.-25° C. under clean and/or dirty conditions.

18. The method of claim 9 , wherein the method does not require a rinse step.

Assignments (1)

Continuity (2)

References Cited (360)